Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Experimental Bapineuzumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Bapineuzumab SC Dose 1; 2 mg | EXPERIMENTAL | - |
| Bapineuzumab SC Dose 2; 7 mg | EXPERIMENTAL | - |
| Bapineuzumab SC Dose 3; 20 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Experimental Bapineuzumab | DRUG | Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo |
Inclusion Criteria: * Diagnosis of probable AD * Age from 50 to less than 89 * Mini-Mental Status Exam score of 18-26 inclusive * Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiv...
Top 20 of 24 competitors
Experimental Bapineuzumab is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is intended for patients with mild to moderate Alzheimer's Disease, as evaluated in a clinical trial. The drug is not approved and remains in clinical development.
Experimental Bapineuzumab is being developed by Johnson & Johnson, which trades under the ticker JNJ. The company is conducting clinical research on this investigational drug for Alzheimer's Disease.
Experimental Bapineuzumab is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with Alzheimer's Disease.
Experimental Bapineuzumab has one completed clinical trial, NCT01254773, titled "Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease." This Phase 2 study enrolled 146 participants in the United States and was placebo-controlled, randomized, and double-blind.
Experimental Bapineuzumab is the same drug as bapineuzumab, with "Experimental" indicating its investigational status. It is being studied for Alzheimer's Disease and has completed a Phase 2 trial under the identifier NCT01254773.